EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Second autologous hematopoietic stem cell transplantation in multiple myeloma

Disha Kakkar, Vivek Mohan iD, Hamza Dalal iD, Subhaprakash Sanyal iD, Rahul Naithani iD

Indian Journal of Cancer · 2026

DOI: 10.4103/ijc.ijc_50_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cancer, 2026. Verfasst von Disha Kakkar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplant, Artemis Hospital, Gurugram, Haryana, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. Second ASCT2 is a salvage option for selected patients with durable remission after ASCT1. Reports from the Asia-Pacific region are limited.

Methods

This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. Demographics, treatment characteristics, toxicity, engraftment, and outcomes were analyzed. All patients underwent fresh stem cell mobilization with granulocyte colony-stimulating factor and plerixafor without cryopreservation.

Results

The median age at ASCT2 was 61 years (range, 47–65 years). The median interval between ASCT1 and ASCT2 was 66 months (range, 31–123 months). Two patients achieved partial remission (PR), 1 achieved very good partial remission (VGPR), and 3 achieved complete remission (CR) before ASCT2. Four patients received melphalan 140 mg/m² and 2 received melphalan 200 mg/m² for ASCT2. The median CD34⁺ cell dose infused during ASCT2 was 2.54 × 10⁶/kg (range, 1.42–21 × 10⁶/kg). Febrile neutropenia developed in 4 patients but was easily controlled with empiric antibiotics. Neutrophil recovery occurred at a median of 11 days (range, 10–14 days), and platelet recovery at 13 days (range, 12–15 days). Hospital stay duration ranged from 15 to 22 days, with a median of 18.5 days. There was no transplant-related mortality. The median follow-up of the study cohort was 28.5 months (range, 1–47 months). Two patients died at 35 and 47 months post-ASCT2, respectively, due to progressive disease. One patient was lost to follow-up after the second bone marrow transplant. Three patients remain alive and in sustained remission.

Conclusion

ASCT2 is a feasible salvage strategy in selected Indian patients with MM, yielding favorable outcomes with acceptable toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationHumansMiddle AgedFemaleMaleTransplantation, AutologousRetrospective StudiesAgedSalvage TherapyMelphalanRemission Induction

Stichwörter der Autor:innen

II BMTmyelomarelapse

Substanzen

Melphalan

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplant, Artemis Hospital, Gurugram, Haryana, India.
  • Department of Hematology and Bone Marrow Transplant, Fortis Institute of Blood Disorders, Fortis Hospital, Mumbai, Maharashtra, India.

ORCID-Profile: Vivek Mohan, Hamza Dalal, Subhaprakash Sanyal, Rahul Naithani

Zitieren

APA

Kakkar, D., Mohan, V., Dalal, H., Sanyal, S., & Naithani, R. (2026). Second autologous hematopoietic stem cell transplantation in multiple myeloma. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_50_26

Vancouver

Kakkar D, Mohan V, Dalal H, Sanyal S, Naithani R. Second autologous hematopoietic stem cell transplantation in multiple myeloma. Indian Journal of Cancer. 2026. doi:10.4103/ijc.ijc_50_26

BibTeX
@article{Kakkar2026,
  author = {Kakkar, Disha and Mohan, Vivek and Dalal, Hamza and Sanyal, Subhaprakash and Naithani, Rahul},
  title = {Second autologous hematopoietic stem cell transplantation in multiple myeloma},
  journal = {Indian Journal of Cancer},
  year = {2026},
  doi = {10.4103/ijc.ijc_50_26}
}
Kostenlos starten →